NH Investment & Securities Co., Ltd. (005940.KS)
KSE - KSE Delayed price. Currency in KRW
Add to watchlist
At close: 03:30PM KST
| Previous close | 11,120.00 |
| Open | 11,010.00 |
| Bid | 11,000.00 x 0 |
| Ask | 11,120.00 x 0 |
| Day's range | 10,920.00 - 11,200.00 |
| 52-week range | 8,890.00 - 13,100.00 |
| Volume | |
| Avg. volume | 884,941 |
| Market cap | 3.786T |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2024 - 29 Apr 2024 |
| Forward dividend & yield | 800.00 (7.19%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | 13,444.00 |
PR NewswireImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide for Dermatomyositis/Polymyositis
ImmunoForge today announced that it has dosed the first patient in its Phase 2 clinical trial to evaluate the efficacy, safety, and pharmacokinetic properties of Froniglutide in patients with dermatomyositis/polymyositis.
PR NewswireImmunoForge Expands Drug Development Licensing Agreement with Duke University
ImmunoForge has announced on the 18th that it has expanded its license rights with Duke University to enhance joint research and drug development opportunities in relation to the elastin-like polypeptide (ELP) platform technology. Through this agreement, ImmunoForge expects to accelerate the development of new drugs based on the ELP technology that was originally developed by Professor Ashutosh Chilkoti at Duke University. Dr. Jim Ballance, Chief Technology Officer (CTO) of ImmunoForge, has pion
© 2024 Yahoo. All rights reserved.